International AIDS Conference

The Latest

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

What Will It Take to Provide HIV Treatment for All?

Despite overwhelming support for starting treatment immediately for everyone living with HIV, there are still many obstacles to treatment access. We asked some HIV experts and community members what it would take to provide HIV treatment for everybody …

By Warren Tong

Four-Day-a-Week ART: Sub-Optimal Drug Levels but Few Virological Failures

"Modern ART is likely to retain viral suppression with significantly less than 100% adherence," Simon Collins writes. "The results might therefore reduce anxiety associated with missed occasional missed doses in someone who otherwise has a good histo...

By Simon Collins for HIV i-Base

Birth Weight and Preterm Delivery Outcomes of Vertically vs Non-Vertically Infected HIV-Positive Pregnant Women

Uninfected infants born to vertically infected HIV-positive women might be at greater risk for lower birth weight than those born to non-vertically infected women, according to findings from the largest cohort of pregnant women to date.

By Polly Clayden for HIV i-Base

Higher Rates of Eye Complications in HIV-Positive People on ART

A prospective South African study looked at rates of optical complications and associations with HIV status and time on ART, and found conditions affecting the external eye, anterior chamber or posterior chamber, but not the neuro-ophthalmic segment,...

By Simon Collins for HIV i-Base

Raltegravir-Based Third-Line ART in Children and Adolescents

Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.

By Polly Clayden for HIV i-Base

Virological Response Without Routine Viral Load Monitoring in Children: Results From the ARROW Trial

Reassuring virological outcomes without routine viral load monitoring shown in the ARROW trial but viral rebound greater than 5000 copies/mL should prompt switch to second-line, according to data presented 8th International Workshop on HIV Paediatric...

By Polly Clayden for HIV i-Base

Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s

Tenofovir DF-containing ART decreases bone mineral density in HIV-positive, breast-feeding women, according to findings presented at the 8th International Workshop on HIV Paediatrics.

By Polly Clayden for HIV i-Base

Raltegravir in HIV-Exposed Neonates

Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.

By Polly Clayden for HIV i-Base

What Is the Cost of Homophobia and Other Systemic Biases?

What are the costs of homophobia, transphobia and other systems of injustice in the eyes of frontline HIV care providers, researchers and advocates?

By Olivia G. Ford